SCHEMBL4025765

SCHEMBL4025765

O=C1c2ccccc2CN1CCCCCN1CCC(c2nc(-c3ccncc3)c(-c3ccc(Cl)c(Cl)c3)[nH]2)CC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.42
DRD2 P14416 5/20 0.42
DRD3 P35462 5/20 0.42
DRD5 P21918 4/20 0.42
HTR7 P34969 2/20 0.42
HTR1A P08908 1/20 0.41
ACHE P22303 1/20 0.39
CCR2 P41597 1/20 0.39
MAPK13 O15264 2/20 0.37
RAF1 P04049 2/20 0.37
MAPK12 P53778 2/20 0.37
MAPK11 Q15759 2/20 0.37
MAPK14 Q16539 2/20 0.37
MAPK9 P45984 1/20 0.37
DRD1 P21728 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7751492 0.94 BRAF (0.40) BRAFDRD2DRD3DRD5HTR7
SCHEMBL4025250 0.88 BRAF (0.43) BRAFDRD2DRD3HTR1AMAPK13
SCHEMBL4024657 0.88 BRAF (0.43) BRAFDRD2DRD3HTR1AMAPK13
SCHEMBL4031401 0.87 BRAF (0.43) BRAFDRD2DRD3HTR1AMAPK13
SCHEMBL4025420 0.86 BRAF (0.43) BRAFHTR1AMAPK13RAF1MAPK12
SCHEMBL4025276 0.84 HTR1A (0.53) DRD2DRD3HTR7HTR1A
SCHEMBL4025679 0.84 HTR1A (0.53) DRD2DRD3HTR7HTR1A
SCHEMBL4027898 0.83 HTR1A (0.51) DRD2DRD3DRD5HTR7HTR1A
SCHEMBL7744430 0.82 BRAF (0.43) BRAFMAPK13RAF1MAPK12MAPK11
SCHEMBL4029363 0.81 HTR1A (0.49) DRD2DRD3DRD5HTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP claimed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP claimed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP claimed
WO-1997012876-A9 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY 1997-09-18 WO claimed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO claimed
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP disclosed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP disclosed
WO-1997012876-A9 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY 1997-09-18 WO disclosed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO disclosed